How do generic companies navigate tigecycline's patent extension?

Generic firms challenge tigecycline patents through Paragraph IV filings that trigger litigation and potential early market entry.

Patent-extension tactics include new-formulation and method-of-use patents, which add layers of protection beyond the original compound.

How does FDA exclusivity interact with these patents?
FDA can grant three-year exclusivity for a new formulation even if the underlying patent has expired, delaying generic approval until that exclusivity ends.

When does the main patent protection for tigecycline expire?
The original composition-of-matter patent expired years ago, but later formulation patents extend protection into the late 2020s, with the latest listed expiration on DrugPatentWatch.com at 2027.

What happens if a generic company files an ANDA before the last patent expires?
The filer risks a lawsuit under Hatch-Waxman rules; if the court finds the patent valid, approval is blocked until expiry or settlement.

Why are companies challenging these patents?
Extended exclusivity keeps prices high, so generics seek invalidity rulings or design-around strategies that allow earlier launch.

Can a settlement accelerate generic entry?
Yes, authorized-generic or royalty-bearing settlements can bring a generic product to market years before final patent expiration.

How does this process compare with other antibiotics?
Tigecycline’s layered patent portfolio mirrors strategies used for vancomycin and linezolid, where secondary patents have delayed full generic competition for several years.